Cargando…

Clinical use of pasireotide for Cushing’s disease in adults

CUSHING’S DISEASE: Excessive corticotroph hormone levels sustained by an adrenocorticotropic hormone-secreting pituitary adenoma lead to a severe clinical condition caused by excess cortisol secretion, called Cushing’s disease (CD). Neurosurgery and radiotherapy are used to treat the pituitary adeno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceccato, Filippo, Scaroni, Carla, Boscaro, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370333/ https://www.ncbi.nlm.nih.gov/pubmed/25834454 http://dx.doi.org/10.2147/TCRM.S37314

Ejemplares similares

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Diabetes Mellitus Secondary to Cushing’s Disease
por: Barbot, Mattia, et al.
Publicado: (2018)

The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
por: Barbot, Mattia, et al.
Publicado: (2019)

Consideration on TMPRSS2 and the risk of COVID-19 infection in Cushing’s syndrome
por: Barbot, Mattia, et al.
Publicado: (2020)

How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing)
por: Scaroni, Carla, et al.
Publicado: (2022)

Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
por: Mondin, Alessandro, et al.
Publicado: (2022)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Pasireotide treatment in Cushing’s disease: A single tertiary center’s experience
por: ŞAHİN, Serdar, et al.
Publicado: (2021)

New treatment guidelines on Cushing's disease
por: Arnaldi, Giorgio, et al.
Publicado: (2009)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
por: Schopohl, Jochen, et al.
Publicado: (2014)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Complications and mortality of Cushing’s disease: report on data collected over a 20-year period at a referral centre
por: Mondin, Alessandro, et al.
Publicado: (2023)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Efficacy and safety of pasireotide for Cushing's disease: A protocol for systematic review and meta-analysis
por: Zhao, Nairui, et al.
Publicado: (2020)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score
por: Parasiliti-Caprino, Mirko, et al.
Publicado: (2021)

Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency
por: Ceccato, Filippo, et al.
Publicado: (2021)

Indication to dynamic and invasive testing in Cushing’s disease according to different neuroradiological findings
por: Ferrante, E., et al.
Publicado: (2021)

Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?
por: Wong, Mimi, et al.
Publicado: (2021)

Frequently asked questions and answers (if any) in patients with adrenal incidentaloma
por: Ceccato, F., et al.
Publicado: (2021)

MON-445 Long-Term Results of an Ongoing Non-Interventional, Real-World Observational Study of Pasireotide SC in Cushing's Disease
por: Yuen, Kevin, et al.
Publicado: (2019)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism
por: Pinelli, Silvia, et al.
Publicado: (2021)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
por: Yedinak, Chris G., et al.
Publicado: (2017)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

Improved salivary cortisol rhythm with dual-release hydrocortisone
por: Ceccato, Filippo, et al.
Publicado: (2018)

Approach to patients with pseudo-Cushing’s states
por: Scaroni, Carla, et al.
Publicado: (2019)

Imaging or Adrenal Vein Sampling Approach in Primary Aldosteronism? A Patient-Based Approach
por: Tizianel, Irene, et al.
Publicado: (2022)

Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas
por: Voltan, Giacomo, et al.
Publicado: (2023)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019)

Frequently Asked Questions in Patients With Adrenal Insufficiency in the Time of COVID-19
por: Sabbadin, Chiara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_do0br1mjbk0l4855832hcsa5f6